<\/p>\n
This is a pre-mixed research peptide supplied as a 50\/50 blend of BPC-157 and TB-500 (Thymosin Beta-4) in a single lyophilized vial. Three total-mg strengths are available: 10 mg<\/strong> (5 mg BPC + 5 mg TB), 20 mg<\/strong> (10 mg + 10 mg), and 30 mg<\/strong> (15 mg + 15 mg) \u2014 each in pack sizes of 10, 20, or 30 vials. The pre-blend saves a reconstitution step for research protocols that study these two compounds together.<\/p>\n<\/div>\n BPC-157 and TB-500 are the two most-studied peptides in the tissue-repair and systemic-recovery research space. They target complementary pathways: BPC-157 (Body Protection Compound, a 15-amino-acid fragment derived from a gastric protein) is investigated for localized tissue repair, angiogenesis, and modulation of growth factors, while TB-500 (a synthetic fragment of Thymosin Beta-4) is studied for systemic cell migration, G-actin sequestration, and broader recovery signaling.<\/p>\n Research protocols that investigate the two compounds together typically dose them in a 1:1 ratio, which is why a pre-mixed 50\/50 blend has become a standard supply format. This product eliminates the extra reconstitution step that would otherwise be required when running a combined-dosing study.<\/p>\n Research labs running combined BPC-157 + TB-500 protocols have two supply choices: (a) order the peptides separately and reconstitute each vial independently, mixing the final doses at injection time, or (b) order a pre-blended vial and reconstitute once.<\/p>\n Both approaches are valid. The blend is chosen most often when:<\/p>\n The individual compounds remain available for protocols that need independent dose-titration of BPC-157 vs TB-500. For background on the individual peptides, see our BPC-157 research guide<\/a> and TB-500 (Thymosin Beta-4) guide<\/a>. For a direct head-to-head treatment, see the BPC-157 vs TB-500 comparison<\/a>.<\/p>\n All three strengths contain the same 1:1 BPC-157 : TB-500 ratio. The total-mg figure refers to the combined peptide mass per vial:<\/p>\n Pack sizes of 10, 20, or 30 vials are available at tiered pricing \u2014 the 20- and 30-vial packs offer meaningful per-vial savings over the 10-vial entry size.<\/p>\n The blend is supplied lyophilized. The working-dilution method is the same as for single-peptide vials:<\/p>\n For a detailed treatment of dilution math and common reconstitution errors, see our BAC Water reconstitution guide<\/a>.<\/p>\n The rationale for studying BPC-157 and TB-500 together rests on their non-overlapping mechanisms. BPC-157 research focuses on localized repair \u2014 angiogenesis, growth-factor modulation (FGF, VEGF, EGF), and tendon-to-bone attachment signaling. TB-500 research targets systemic cell migration, G-actin binding, and broader inflammation-resolution pathways. In combination research protocols, investigators hypothesize additive or even synergistic effects across the overlap zone between localized and systemic recovery.<\/p>\n Typical reported research-protocol dose ranges (per peptide component):<\/p>\n These figures reflect published research protocols and are not prescribing recommendations. Neither BPC-157 nor TB-500 is approved for human therapeutic use by the FDA, EMA, MHRA, or TGA. Both are supplied as research compounds for laboratory investigation only.<\/p>\n \ud83d\udce6 Every order is covered by our Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days, we reship it.<\/p>\nBPC-157 + TB-500 Blend \u2014 Pre-Mixed Dual-Peptide Research Compound<\/h2>\n
Why a Blend Instead of Two Separate Vials?<\/h2>\n
\n
Strength Options \u2014 How to Choose<\/h2>\n
\n
Reconstitution \u2014 Standard Research Protocol<\/h2>\n
\n
Research Context \u2014 Combined BPC + TB Dosing<\/h2>\n
\n
Storage & Handling<\/h2>\n
\n